Two-drug combo to reduce low white blood cell counts in advanced colorectal cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs—bevacizumab and trifluridine/tipiracil—given together to see if it lowers the risk of a serious drop in white blood cells (neutropenia) in people with advanced colorectal cancer. The goal is to make treatment safer and more tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage IV colorectal cancer that has spread.
- You have already tried chemotherapy with fluoropyrimidine, oxaliplatin, irinotecan, and certain targeted therapies (bevacizumab, aflibercept, cetuximab, or panitumumab).
- You are in good enough health to carry out daily activities (ECOG 0 or 1).
- Your blood counts, kidney, and liver function meet minimum levels.
- You can swallow tablets and are willing to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
This study tests a combination of two drugs, trifluridine and tipiracil, for people whose colorectal cancer has spread to other parts of the body. The goal is to see how well this treatment works in real life and if it can help you live longer or feel better.
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.